Shares of Bruker Biosciences gained 13.4 percent for the trading week ended Tuesday, reversing a 7-percent decline the week before. The firm led the seven companies in the BCW Index that gained ground for the tracking period. Stratagene led decliners in the Index with a drop of 9.3 percent. Its shares reached a 52-week low of $5.51 on Tuesday before closing at $5.67.

Overall, the Index gained .1 percent for the week. In comparison, the Dow Jones Industrial Average fell .5 percent, the Nasdaq dropped .3 percent, and the Nasdaq Biotech Index declined .7 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.